Advertisement
Advertisement
CGON
CG Oncology, Inc. Common stock
74.62
USDSponsored
-1.00
-1.32%
Sep 18, 15:59 UTC -4
Closed
After-Market
72.49
-2.13
-2.85%
CGON Earnings Reports
Positive Surprise Ratio
CGON beat 4 of 11 last estimates.
36%
Next Report
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$544.85K
/-$0.85
Implied change from Q2 26 (Revenue/ EPS)
-52.91%
/-5.56%
Implied change from Q3 25 (Revenue/ EPS)
-67.30%
/+51.79%
CG Oncology, Inc. Common stock earnings per share and revenue
On Aug 06, 2026, CGON reported earnings of -0.90 USD per share (EPS) for Q2 26, missing the estimate of -0.67 USD, resulting in a -32.82% surprise. Revenue reached 1.16 million, compared to an expected 367.63 thousand, with a 214.72% difference. The market reacted with a +3.36% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.85 USD, with revenue projected to reach 544.85 thousand USD, implying an decrease of -5.56% EPS, and decrease of -52.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were CG Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, CG Oncology, Inc. Common stock reported EPS of -$0.90, missing estimates by -32.82%, and revenue of $1.16M, 214.72% above expectations.
How did the market react to CG Oncology, Inc. Common stock's Q2 2026 earnings?
The stock price moved up 3.36%, changed from $72.42 before the earnings release to $74.85 the day after.
When is CG Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for CG Oncology, Inc. Common stock's next earnings report?
Based on 11
analysts, CG Oncology, Inc. Common stock is expected to report EPS of -$0.85 and revenue of $544.85K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.